Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Open accessThe DOI matches its Crossref record; 506 of the 506 references it cites were found in a registry or an index.
Abstract
Drug designing and development is an important area of research for pharmaceutical companies and chemical scientists. However, low efficacy, off-target delivery, time consumption, and high cost impose a hurdle and challenges that impact drug design and discovery. Further, complex and big data from genomics, proteomics, microarray data, and clinical trials also impose an obstacle in the drug discovery pipeline. Artificial intelligence and machine learning technology play a crucial role in drug discovery and development. In other words, artificial neural networks and deep learning algorithms have modernized the area. Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, polypharmacology, and physiochemical activity. Evidence from the past strengthens the implementation of artificial intelligence and deep learning in this field. Moreover, novel data mining, curation, and management techniques provided critical support to recently developed modeling algorithms. In summary, artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind. The primary concern associated with drug design and development is time consumption and production cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms can eliminate the challenges and hurdles of traditional drug design and development. Artificial intelligence is referred to as superset comprising machine learning, whereas machine learning comprises supervised learning, unsupervised learning, and reinforcement learning. Further, deep learning, a subset of machine learning, has been extensively implemented in drug design and development. The artificial neural network, deep neural network, support vector machines, classification and regression, generative adversarial networks, symbolic learning, and meta-learning are examples of the algorithms applied to the drug design and discovery process. Artificial intelligence has been applied to different areas of drug design and development process, such as from peptide synthesis to molecule design, virtual screening to molecular docking, quantitative structure-activity relationship to drug repositioning, protein misfolding to protein-protein interactions, and molecular pathway identification to polypharmacology. Artificial intelligence principles have been applied to the classification of active and inactive, monitoring drug release, pre-clinical and clinical development, primary and secondary drug screening, biomarker development, pharmaceutical manufacturing, bioactivity identification and physiochemical properties, prediction of toxicity, and identification of mode of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artificial Intelligence may allow for more accurate personalisation of therapy to predict the optimum ‘cocktail’ of mono agonist therapies based on the genetics and metabolomics of an individual and may quicken the process of drug development [70, 71].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These authors trained a DL algorithm on a large dataset of known cancer-related compounds and their corresponding biological activity. As an output, novel compounds with high potential for future cancer treatment were obtained, demonstrating the ability of this method to discover new therapeutic candidates.”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, the successful use of AI to identify novel compounds for the treatment of cancer has recently been reported by Gupta, R., et al. [21].”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 506
Inductive transfer learning for molecular activity prediction: Next-Gen QSAR Models with MolPMoFiT
Li, X., & Fourches, D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00430-x · Cited by 171 · cited 1×
“In the subsequent steps, the organization is prepared to get familiar with the SMILES syntax with a huge preparing set [432, 433].”
MethodDeep Learning and Virtual Drug Screening
Carpenter, K. A., Cohen, D. S., Jarrell, J. T., & Huang, X. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0314 · Cited by 170 · cited 1×
“Further, ML models such as PARASHIFT, HEX, USR, and ShaPE algorithms have been constructed for LBVS [168, 169].”
MethodDrug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., & Barbieri, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.017 · Cited by 167 · cited 1×
“ML algorithms replace the chemical similarity and molecular docking-based conventional methods with new system biology methods, which can evaluate drug effects [270–273].”
MethodBeck, T., Hastings, R. K., Gollapudi, S., Free, R. C., & Brookes, A. J. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.274 · Cited by 166 · cited 1×
“GWAS central (https:// www. gwasc entral. org/) [46], NHGRI-EBI GWAS Catalog (https:// www. ebi. ac. uk/ gwas/ home) [47] are some of the repositories which contain GWAS data.”
BackgroundArtificial Intelligence in Nephrology: Core Concepts, Clinical Applications, and Perspectives
Niel, O., & Bastard, P. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.020 · Cited by 165 · cited 1×
“…in AI have impacted clinical pharmacology in many ways like literature searching and processing, interactions with online predictive ML models, ML methods in framing policy to encourage healthcare in many countries and also to get predictive analysis for drug-related information [449, 450].”
MethodArtificial intelligence in chemistry and drug design
Brown, N., Ertl, P., Lewis, R., Luksch, T., Reker, D., & Schneider, N. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00317-x · Cited by 165 · cited 1×
“Further, AI models eliminate the toxicity problems, which arise due to off-target interactions [10].”
BackgroundInterpretable Deep Learning in Drug Discovery
Preuer, K., Klambauer, G., Rippmann, F., Hochreiter, S., & Unterthiner, T. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-28954-6_18 · Cited by 165
De Novo Design at the Edge of Chaos: Miniperspective
Schneider, P., & Schneider, G. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01849 · Cited by 164 · cited 1×
“Further, the field has seen some recovery recently because of advancements in the field of AI [421, 422].”
BackgroundVirtual screening for the discovery of bioactive natural products
Rollinger, J. M., Stuppner, H., & Langer, T. (2008) · Natural Compounds as Drugs Volume I · doi:10.1007/978-3-7643-8117-2_6 · Cited by 163 · cited 1×
“These models construct large 3D data sets developed via in silico experiments or in house compound collection [130].”
BackgroundBuilding high-level features using large scale unsupervised learning
Le, Q. V., Ranzato, M., Monga, R., Devin, M., Chen, K., Corrado, G. S., Dean, J., & Ng, A. Y. (2011) · arXiv (Cornell University) · doi:10.48550/arxiv.1112.6209 · Cited by 163
Looking beyond the hype: applied AI and machine learning in translational medicine
Toh, T. S., Dondelinger, F., & Wang, D. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.027 · Cited by 159 · cited 1×
“AI models can also reduce the cost of clinical trials by enhancing the success rate by analyzing toxicity, side effects, and other related parameters [455].”
BackgroundWill Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology?
Zhavoronkov, A., Vanhaelen, Q., & Oprea, T. I. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1795 · Cited by 159 · cited 1×
“…organic compounds with the help of computer programs, designing new compounds, developing assays, and predicting the 3D structure of target molecules are some time-consuming and tiresome tasks which with the help of AI can be reduced and can speed up the process of drug discovery [94, 95].”
BackgroundMachine Learning on DNA-Encoded Libraries: A New Paradigm for Hit Finding
McCloskey, K., Sigel, E. A., Kearnes, S., Xue, L., Tian, X., Moccia, D., Gikunju, D., Bazzaz, S., Chan, B., Clark, M. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00452 · Cited by 158
Merging Systems Biology with Pharmacodynamics
Iyengar, R., Zhao, S., Chung, S.-W., Mager, D. E., & Gallo, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003563 · Cited by 156 · cited 1×
“ML algorithms replace the chemical similarity and molecular docking-based conventional methods with new system biology methods, which can evaluate drug effects [270–273].”
MethodTang, J., Liu, R., Zhang, Y.-L., Liu, M.-Z., Hu, Y.-F., Shao, M.-J., Zhu, L.-J., Xin, H.-W., Feng, G.-W., Shang, W.-J., et al. (2017) · Scientific Reports · doi:10.1038/srep42192 · Cited by 154 · cited 1×
“Likewise, Tang et al. [127] used ML techniques like ANN, Bayesian additive regression trees, boosted regression trees, multivariate adaptive regression splines to determine the optimum dose of immunosuppressive drug Tacrolimus.”
MethodZhuang, C., Narayanapillai, S., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 154 · cited 1×
“…signal transducer and activator of transcription 3 dimerization inhibitor [184], prediction of VHL and hypoxia-inducible factor 1-alpha inhibitors [185], and prediction of Kelch-like ECH-associated protein-nuclear factor erythroid 2-related factor 2 (Keap-Nrf2) small-molecule inhibitors [186].”
BackgroundUtilization of a least square support vector machine (LSSVM) for slope stability analysis
Samui, P., & Kothari, D. P. (2011) · Scientia Iranica · doi:10.1016/j.scient.2011.03.007 · Cited by 154 · cited 1×
“A study suggests that least-square SVM (LS-SVM) showed the highest classification accuracy of 95.34% [97, 98].”
MethodInfluentialOld friends in new guise: repositioning of known drugs with structural bioinformatics
Haupt, V. J., & Schroeder, M. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr011 · Cited by 153
Yue, S., Liu, J., Feng, W., Zhang, F., Chen, J., Xin, L.-T., Peng, C. Y., Guan, H., Wang, C., & Yan, D. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00694 · Cited by 150 · cited 1×
“For example, synergistic mechanism of huangqi and huanglian for Diabetes Mellitus [366], investigation of blood enriching mechanism of danggui buxue decoction [367], and prediction of multiple mechanisms of Hedyotis diffusa Willd.”
BackgroundVEGA-QSAR: AI Inside a Platform for Predictive Toxicology.
Benfenati, E., Manganaro, A., & Gini, G. C. (2013) · Virtual Community of Pathological Anatomy (University of Castilla La Mancha) · Cited by 144
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2016) · Scientific Reports · doi:10.1038/srep29575 · Cited by 143
Wu, Z., Cheng, F., Li, J., Li, W., Liu, G., & Tang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw012 · Cited by 143 · cited 1×
“Finally, validation of repurposed drugs is carried out through clinical trials, in vitro studies, and in vivo studies ◂ phenome-wide drug repositioning for schizophrenia and prediction of drug-target interactions, respectively [289, 290].”
MethodCharacterizing the Binding Sites for GK Domain of DLG1 and DLG4 via Molecular Dynamics Simulation
Li, H., Chen, Q., Shan, C., Guo, C., Yang, X., Chen, Y., Zhu, J., & Ouyang, Q. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00001 · Cited by 143
Novel paradigms for drug discovery: computational multitarget screening
Jenwitheesuk, E., HORST, J., Rivas, K. L., VanVoorhis, W. C., & Samudrala, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.007 · Cited by 141 · cited 1×
“One of the significant outcomes of AI and ML algorithms in drug discovery and development is the prediction and estimation of overall topology and dynamics of disease network or drug-drug interaction or drug-target relationships [349].”
BackgroundComputational approaches for drug design and discovery: An overview
Baldi, A. (2010) · Systematic Reviews in Pharmacy · doi:10.4103/0975-8453.59519 · Cited by 141 · cited 1×
“However, many issues like time cost, computational cost, and reliability, are still associated with traditional computational methods [70, 71].”
BackgroundMachine learning-guided discovery and design of non-hemolytic peptides
Plisson, F., Ramírez-Sánchez, O., & Martínez-Hernández, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-73644-6 · Cited by 137 · cited 1×
“Likewise, Plisson et al. 2020 combined the ML algorithm with an outlier detection technique to discover AMPs with non-hemolytic profiles [111].”
MethodDriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies
Han, Y., Yang, J., Qian, X., Cheng, W.-C., Liu, S.-H., Hua, X., Zhou, L., Yang, Y., Wu, Q., Liu, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz096 · Cited by 136 · cited 10×
“However, with AI, quantum mechanics can get more user-friendly and efficacious.”
MethodInfluentialBøgevig, A., Federsel, H.-J., Huerta, F., Hutchings, M. G., Kraut, H., Langer, T., Löw, P., Oppawsky, C., Rein, T., & Saller, H. (2015) · Organic Process Research & Development · doi:10.1021/op500373e · Cited by 136
Struct2Net: a web service to predict protein-protein interactions using a structure-based approach
Singh, R., Park, D., Xu, J., Hosur, R., & Berger, B. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq481 · Cited by 136 · cited 1×
“Structure-based threading logistic regression tool Struct2Net (http:// struc t2net. csail. mit . edu ) to evaluate the probability of interaction is the first structure-based PPI predictor apart from homology modeling [155].”
MethodDrug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135 · cited 1×
“…with a small number of people; Phase 2, drug efficacy testing with the small number of human subjects affected by a particular disease; Phase 3, efficacy studies with a large number of patients and after passing the clinical trials FDA reviews it for approval and commercialization [451, 452].”
BackgroundPires, D. E. V., & Ascher, D. B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw458 · Cited by 134
Governance of automated image analysis and artificial intelligence analytics in healthcare
Ho, C. W. L., Soon, D., Caals, K., & Kapur, J. (2019) · Clinical Radiology · doi:10.1016/j.crad.2019.02.005 · Cited by 132
Awale, M., & Reymond, J. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0199-x · Cited by 130 · cited 1×
“…tools and stand-alone software packages for polypharmacology prediction such as polypharmacology browser (PPB) (http:// www. gdb . unibe. ch /) [356], TarPred (http:// www. dddc. ac . cn / tarpr ed/) [140], Self-Organizing Map Based Prediction of Drug Equivalence Relationship (SPiDER) (http://…”
Backgroundde Graaf, C., & Rognan, D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800710x · Cited by 129
Gao, L., Wang, K., Zhou, Y., Fang, J., Qin, X., & Du, G. (2018) · Scientific Reports · doi:10.1038/s41598-017-18325-7 · Cited by 129
Shi, X.-Q., Yue, S., Tang, Y., Chen, Y., Zhou, G., Zhang, J., Zhu, Z., Liu, P., & Duan, J. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.01.027 · Cited by 128 · cited 1×
“For example, synergistic mechanism of huangqi and huanglian for Diabetes Mellitus [366], investigation of blood enriching mechanism of danggui buxue decoction [367], and prediction of multiple mechanisms of Hedyotis diffusa Willd.”
BackgroundLeveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects
Julkunen, H., Cichonska, A., Gautam, P., Szedmak, S., Douat, J., Pahikkala, T., Aittokallio, T., & Rousu, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19950-z · Cited by 128 · cited 1×
“Further, Julkunen et al. [124] devised comboFM (https:// github. com/ aalto- ics-kepaco/ combo FM), a novel ML-driven tool, which ascertain appropriate drug combinations and dose in pre-clinical studies like cancer cell lines. com-boFM determines appropriate drug combinations and dose by using…”
PubMed: The Bibliographic Database
Canese, K., & Weis, S. (2013) · Cited by 128
Pantuck, A. J., Lee, D., Kee, T., Wang, P., Lakhotia, S., Silverman, M. H., Mathis, C., Drakaki, A., Belldegrun, A. S., Ho, C., et al. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800104 · Cited by 127
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Vidler, L. R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H., Brown, N., Knapp, S., & Hoelder, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011302 · Cited by 126 · cited 1×
“…agonists [181], screening of partial agonists of the β2 adrenergic receptor [182], identification of bromodomain-containing protein 4 inhibitors [183], discovery of natural product-like signal transducer and activator of transcription 3 dimerization inhibitor [184], prediction of VHL and…”
BackgroundDesign, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent
Rashid, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103576 · Cited by 126 · cited 1×
“In the same study, the author calculated molecular properties of compounds through Lipinski’s rule of five and predicted the pre-ADMET properties of the synthetic compounds [309].”
MethodAmbure, P. S., Halder, A. K., González‐Díaz, H., & Cordeiro, M. N. D. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00295 · Cited by 126
Using artificial intelligence methods to speed up drug discovery
Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1621284 · Cited by 124 · cited 1×
“The most infuriating point is that nine out of ten drug molecules usually fail to pass phase II clinical trials and other regulatory approvals [106–108].”
BackgroundSchuster, D., Maurer, E. M., Laggner, C., Nashev, L. G., Wilckens, T., Langer, T., & Odermatt, A. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600794 · Cited by 124 · cited 1×
“…development through cell-culture analysis, animal model experimentation, and patient analysis ◂ established using the CATALYST program (www. accel rys. com), and a group of researchers was successful in predicting 11β-hydroxysteroid dehydrogenase type 1 inhibitors using the VS experiments [131].”
MethodThomas, S. N., Funk, K. E., Wan, Y., Liao, Z., Davies, P., Kuret, J., & Yang, A. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0893-0 · Cited by 123 · cited 1×
“Further, [463] used a combination of protein–protein interaction networks, autoencoder, and SVM to predict novel target genes associated with PD. Likewise, [464] used ML models like RF, DT, generalized linear model, and rule induction to find out risk genes of HD through gene expression profiling.”
Methodvan IJzendoorn, D. G. P., Szuhai, K., Bruijn, I. H. B., Kostine, M., Kuijjer, M. L., & Bovée, J. V. M. G. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006826 · Cited by 123 · cited 1×
“For example, using the ML approach and gene expression data, van IJzendoorn et al. 2019 found out novel biomarkers and potential drug targets for rare soft tissue sarcoma [44].”
MethodLiu, L.-J., Leung, K.-H., Chan, D. S.-H., Wang, Y.-T., Ma, D.-L., & Leung, C.-H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.250 · Cited by 122 · cited 1×
“…protein 4 inhibitors [183], discovery of natural product-like signal transducer and activator of transcription 3 dimerization inhibitor [184], prediction of VHL and hypoxia-inducible factor 1-alpha inhibitors [185], and prediction of Kelch-like ECH-associated protein-nuclear factor…”
BackgroundRifaioğlu, A. S., Çetin-Atalay, R., Kahraman, D., Doğan, T., Martin, M. J., & Atalay, V. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa858 · Cited by 120
Amin, S. A., Ghosh, K., Gayen, S., & Jha, T. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1780946 · Cited by 120
Fang, J., Li, Y., Liu, R., Pang, X., Li, C., Yang, R., He, Y., Lian, W., Liu, A.-L., & Du, G.-H. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500574n · Cited by 118 · cited 1×
“…of human copper trafficking blocker in cancer [369], identification of multi-target ligands through chemical-protein interaction in AD [370], prediction of the anticancer mechanism of Kushen Injection against Hepato-cellular carcinoma [371], and discovery of Pteridin-7(8H)- one-Based…”
BackgroundHassan-Harrirou, H., Zhang, C., & Lemmin, T. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00075 · Cited by 118
Identification of Nonpeptide CCR5 Receptor Agonists by Structure-based Virtual Screening
Kellenberger, E., Springael, J., Parmentier, M., Hachet‐Haas, M., Galzi, J., & Rognan, D. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061389p · Cited by 117 · cited 1×
“…hypothesis that AI plays a critical role in SBVS, such as identification of non-peptide cysteine-cysteine chemokine receptor 5 receptor agonists [181], screening of partial agonists of the β2 adrenergic receptor [182], identification of bromodomain-containing protein 4 inhibitors [183],…”
BackgroundAdvances and Perspectives in Applying Deep Learning for Drug Design and Discovery
Lipinski, C. F., Maltarollo, V. G., Oliveira, P. R., da Silva, A. B. F., & Honório, K. M. (2019) · Frontiers in Robotics and AI · doi:10.3389/frobt.2019.00108 · Cited by 117 · cited 1×
“From the past two decades, the development of efficient and advanced systems for the targeted delivery of therapeutic agents with maximum efficiency and minimum risks has imposed a great challenge among chemical and biological scientists [1].”
BackgroundVirtual Screening: A Fast Tool for Drug Design
Vyas, V. K. (2008) · Scientia Pharmaceutica · doi:10.3797/scipharm.0803-03 · Cited by 117 · cited 1×
“As a subset of AI, ML is a technique for coordinating VS for drug leads, which generally incorporates gathering a filtered set of compounds, containing known actives and inactive compounds to train a model [423, 424].”
MethodPredicting Parkinson's Disease Genes Based on Node2vec and Autoencoder
Peng, J., Guan, J., & Shang, X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00226 · Cited by 116 · cited 1×
“Further, [463] used a combination of protein–protein interaction networks, autoencoder, and SVM to predict novel target genes associated with PD. Likewise, [464] used ML models like RF, DT, generalized linear model, and rule induction to find out risk genes of HD through gene expression profiling.”
MethodiDrug: Integration of drug repositioning and drug-target prediction via cross-network embedding
Chen, H., Cheng, F., & Li, J. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008040 · Cited by 116 · cited 2×
“The efficiency and effectiveness of iDrug allow users to understand novel clinical insights of drug-target-disease mechanisms [292].”
BackgroundMethodCSM-lig: a web server for assessing and comparing protein-small molecule affinities
Pires, D. E. V., & Ascher, D. B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw390 · Cited by 115
Chematica: A Story of Computer Code That Started to Think like a Chemist
Grzybowski, B. A., Szymkuć, S., Gajewska, E. P., Molga, K., Dittwald, P., Wołos, A., & Klucznik, T. (2018) · Chem · doi:10.1016/j.chempr.2018.02.024 · Cited by 114
Integration of single-cell RNA-seq data into population models to characterize cancer metabolism
Damiani, C., Maspero, D., Di Filippo, M., Colombo, R., Pescini, D., Graudenzi, A., Westerhoff, H. V., Alberghina, L., Vanoni, M., & Mauri, G. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006733 · Cited by 113
Profiling Prediction of Kinase Inhibitors: Toward the Virtual Assay
Merget, B., Turk, S., Eid, S., Rippmann, F., & Fulle, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01611 · Cited by 112
In silico Prediction of Drug Induced Liver Toxicity Using Substructure Pattern Recognition Method
Zhang, C., Cheng, F., Li, W., Liu, G., Lee, P. W., & Tang, Y. (2016) · Molecular Informatics · doi:10.1002/minf.201500055 · Cited by 111
Reis, J., Cagide, F., Chavarria, D., Silva, T., Fernandes, C., Gaspar, A., Uriarte, E., Remião, F., Alcaro, S., Ortuso, F., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00527 · Cited by 111
Goh, G. B., Siegel, C., Vishnu, A., Hodas, N. O., & Baker, N. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1706.06689 · Cited by 111 · cited 1×
“…characteristics features of drug compounds such as SMILES2Vec (predicts chemical properties) [339], Chemception (DNN-based prediction of chemical properties) [245], DeepSynergy (prediction of anti-cancer drug synergy with DL) [340], and deepAOT (prediction of compound acute oral toxicity) [341].”
BackgroundChambers, J. C., Abbott, J., Zhang, W., Turro, E., Scott, W. R., Tan, S.-T., Afzal, U., Afaq, S., Loh, M., Lehne, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102645 · Cited by 110
Matched Molecular Pair Analysis in Short: Algorithms, Applications and Limitations
Tyrchan, C., & Evertsson, E. (2017) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.12.003 · Cited by 109 · cited 1×
“MMP is associated with a single change in a drug candidate, which further influences the bioactivity of the compound [102].”
BackgroundPTPD: predicting therapeutic peptides by deep learning and word2vec
Wu, C., Gao, R., Zhang, Y., & De Marinis, Y. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3006-z · Cited by 109 · cited 1×
“Likewise, Wu et al. [117] proposed PTPD, a tool based on CNN and word2vec, for the discovery of novel peptides for therapeutics.”
MethodHandbook of Neural Network Signal Processing
Rigelsford, J. (2003) · Industrial Robot the international journal of robotics research and application · doi:10.1108/ir.2003.04930dae.002 · Cited by 109
Biophysical prediction of protein–peptide interactions and signaling networks using machine learning
Cunningham, J. M., Rogers, J. R., Koytiger, G., Sorger, P. K., & AlQuraishi, M. (2020) · Nature Methods · doi:10.1038/s41592-019-0687-1 · Cited by 108 · cited 1×
“To predict these PBDs across multiple protein families bespoke ML tool was developed, known as hierarchical statistical mechanical modeling (HSMM) [152].”
MethodTransforming Computational Drug Discovery with Machine Learning and AI
Smith, J. S., Roitberg, A. E., & Isayev, O. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00437 · Cited by 107 · cited 1×
“Moreover, with the advent of ML-based tools, it has become relatively easier to determine the three-dimensional structure of a target protein, which is a critical step in drug discovery, as novel drugs are designed based on the three-dimensional ligand biding environment of a protein [72, 73].”
BackgroundLearning with multiple pairwise kernels for drug bioactivity prediction
Cichońska, A., Pahikkala, T., Szedmák, S., Julkunen, H., Airola, A., Heinonen, M., Aittokallio, T. A., & Rousu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty277 · Cited by 107 · cited 1×
“Likewise, Cichonska et al. [132] developed pairwiseMKL (https:// github. com/ aalto- ics-kepaco), a multiple kernel learning-based method, for determining the bioactivity of compounds [133].”
MethodLei, T., Sun, H., Kang, Y., Zhu, F., Liu, H., Zhou, W., Wang, Z., Li, D., Li, Y., & Hou, T. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00631 · Cited by 105
Gahlawat, A., Kumar, N., Kumar, R., Sandhu, H., Singh, I. P., Singh, S., Sjöstedt, A. B., & Garg, P. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00546 · Cited by 104 · cited 1×
“…acid, and 11m_32045235 were promising therapeutic compound against SARS-Cov-2 main protease, whereas Selvaraj et al. 2020 demonstrated that TCM 57,025, TCM 3495, TCM 5376, TCM 20,111, and TCM 31,007 were therapeutic compounds that interact with the substrate-binding site of N7-MTase [194, 195].”
BackgroundFL-QSAR: a federated learning-based QSAR prototype for collaborative drug discovery
Chen, S., Xue, D., Chuai, G., Yang, Q., & Liu, Q. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa1006 · Cited by 103
Interaction prediction in structure-based virtual screening using deep learning
Gonczarek, A., Tomczak, J. M., Zaręba, S., Kaczmar, J., Dąbrowski, P., & Walczak, M. J. (2018) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2017.09.007 · Cited by 100 · cited 1×
“In general, there are two important types of VS that are structure-based VS (SBVS) and ligand-based VS (LBVS) [159, 160].”
BackgroundIAMPE: NMR-Assisted Computational Prediction of Antimicrobial Peptides
Kavousi, K., Bagheri, M., Behrouzi, S., Vafadar, S., Atanaki, F. F., Lotfabadi, B. T., Ariaeenejad, S., Shockravi, A., & Moosavi‐Movahedi, A. A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00841 · Cited by 99 · cited 1×
“In addition, Kavousi et al. developed IAMPE (http:// cbb1. ut. ac. ir/), a web server for the identification of anti-microbial peptides, which integrates 13 CNMR-based features and physicochemical features of peptides as input to ML algorithms, in order to identify novel AMPs [112].”
BackgroundSelvaraj, C., Dinesh, D. C., Panwar, U., Abhirami, R., Bouřa, E., & Singh, S. K. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1778535 · Cited by 99 · cited 2×
“…acid, and 11m_32045235 were promising therapeutic compound against SARS-Cov-2 main protease, whereas Selvaraj et al. 2020 demonstrated that TCM 57,025, TCM 3495, TCM 5376, TCM 20,111, and TCM 31,007 were therapeutic compounds that interact with the substrate-binding site of N7-MTase [194, 195].”
BackgroundGrand challenges for cheminformatics
Wild, D. J. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-1 · Cited by 98
Alberga, D., Gambacorta, N., Trisciuzzi, D., Ciriaco, F., Amoroso, N., & Nicolotti, O. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00517 · Cited by 97 · cited 1×
“The results indicated that AI and multi-objective optimization allows capturing the latent links joining chemical and biological aspects, thus providing easy-to-use options for customizable design strategies, which proved especially effective for both lead generation and lead optimization [436].”
BackgroundFlexX‐Scan: Fast, structure‐based virtual screening
Schellhammer, I., & Rarey, M. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20217 · Cited by 96
Hornig, M., & Klamt, A. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci0501948 · Cited by 93
Performance Evaluation of cuDNN Convolution Algorithms on NVIDIA Volta GPUs
Jordà, M., Valero‐Lara, P., & Peña, A. J. (2019) · IEEE Access · doi:10.1109/access.2019.2918851 · Cited by 93 · cited 1×
“In 2014 Nvidia introduced CUDA deep neural network (cuDNN), a CUDA-based DL library, which accelerated DL-based operations [35].”
LigBuilder V3: A Multi-Target de novo Drug Design Approach
Yuan, Y., Pei, J., & Lai, L. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00142 · Cited by 92 · cited 1×
“LigBuilder V3 is again used for multi-target drug plans and enhancement, particularly for compact ligands for proteins with varying ligand binding sites [440].”
MethodIdentification of potent and selective small molecule inhibitors of the cation channel TRPM4
Ozhathil, L. C., Delalande, C., Bianchi, B., Németh, G., Kappel, S., Thomet, U., Ross‐Kaschitza, D., Simonin, C., Rubin, M., Gertsch, J., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14220 · Cited by 91 · cited 2×
“…of lysophosphatidic acid acyltransferase β as a therapeutic target of nanomolar angiogenesis, whereas Ozhathil et al. 2018 identified potent and selective small-molecule inhibitors of cation channel transient receptor potential cation channel subfamily M member 4 using PPB [362, 363].”
MethodRopp, P. J., Spiegel, J. O., Walker, J. L., Green, H., Morales, G. A., Milliken, K. A., Ringe, J. J., & Durrant, J. D. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0358-3 · Cited by 91 · cited 1×
“…EasyVS (http:// biosig. unime lb. edu. au/ easyvs) [175], DEKOIS 2.0 [176], PL-PatchSurfer2 (http:// www. kihar alab. org/ plps2/) [177], SPOT-ligand 2 (http:// sparks-lab. org/) [178], Gypsum-DL (https:// durra ntlab. pitt. edu/ gypsum-dl/) [179], and ENRI [180] have been developed for SBVS.”
InfluentialHu, J., Liu, Z., Yu, D.-J., & Zhang, Y. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty081 · Cited by 90
Yu, L., Jing, R., Liu, F., Luo, J., & Li, Y. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.10.005 · Cited by 90 · cited 1×
“Moreover, Yu et al. [114] proposed DeepACP, a deep recurrent neural network-based model for identifying anti-cancer peptides.”
BackgroundWang, Z., Zhou, M., & Arnold, C. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa437 · Cited by 90 · cited 2×
“The results demonstrated that BiFusion achieved improved performance than multiple baselines for drug repurposing [295].”
BackgroundMethodA novel descriptor based on atom-pair properties
Kuroda, M. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-016-0187-6 · Cited by 90
An integrative machine learning approach for prediction of toxicity-related drug safety
Lysenko, A., Sharma, A., Boroevich, K. A., & Tsunoda, T. (2018) · Life Science Alliance · doi:10.26508/lsa.201800098 · Cited by 88 · cited 1×
“…prediction software and web-based tools such as Tox21 (https:// ntp. niehs. nih. gov/ whatw estudy/ tox21/ index. html) [327], SEA (http:// sea. bkslab. org/) [328], eToxPred (https:// www. bryli nski. org/ etoxp red-0) [329], and TargeTox (https:// github. com/ artem-lysen ko/ Targe Tox) [330].”
Meta-QSAR: a large-scale application of meta-learning to drug design and discovery
Olier, I., Sadawi, N., Bickerton, G. R., Vanschoren, J., Grosan, C., Soldatova, L., & King, R. D. (2018) · Machine Learning · doi:10.1007/s10994-017-5685-x · Cited by 88
Arcon, J. P., Modenutti, C. P., Avendaño, D., Lopez, E. D., Defelipe, L. A., Ambrosio, F. A., Turjanski, A. G., Forli, S., & Marti, M. A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz152 · Cited by 86 · cited 1×
“…rader/) [205], QEX [206], IVS2vec (https:// github. com/ haipi ng1010/ IVS2V ec) [207], AutoDock Bias (http:// autod ockbi as. wordp ress. com/) [208], Ligity [209], D3Similarity (https:// www. d3pha rma. com/ D3Tar gets- 2019-nCoV/ D3Sim ilari ty/ index. php) [210], and GCAC (http:// ccbb.…”
Wang, Y., Wang, F., Shi, X.-X., Jia, C., Wu, F., Hao, G., & Yang, G. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa276 · Cited by 85
Chatterjee, P., Basu, S., Kundu, M., Nasipuri, M., & Plewczyński, D. (2011) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-011-0008-x · Cited by 85
ChemGrapher: Optical Graph Recognition of Chemical Compounds by Deep Learning
Oldenhof, M., Arany, Á., Moreau, Y., & Simm, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00459 · Cited by 84
Lei, T., Chen, F., Liu, H., Sun, H., Kang, Y., Li, D., Li, Y., & Hou, T. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00317 · Cited by 84
Enabling future drug discovery by de novo design
Hartenfeller, M., & Schneider, G. (2011) · WIREs Computational Molecular Science · doi:10.1002/wcms.49 · Cited by 83
Ferraz, W. R., Gomes, R. A., Novaes, A. L. S., & Trossini, G. H. G. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0165 · Cited by 82
Gadaleta, D., Manganelli, S., Roncaglioni, A., Toma, C., Benfenati, E., & Mombelli, E. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00297 · Cited by 81
Büyükbingöl, E., Sisman, A., Akyıldız, M., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.065 · Cited by 80
Prediction of Human Intestinal Absorption of Compounds Using Artificial Intelligence Techniques
Kumar, R., Sharma, A., Siddiqui, M. H., & Tiwari, R. K. (2017) · Current Drug Discovery Technologies · doi:10.2174/1570163814666170404160911 · Cited by 79 · cited 1×
“Among the above-said models, SVM has higher accuracy of 91.54% [302].”
MethodInfluentialJamal, S., Goyal, S., Shanker, A., & Grover, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00908-z · Cited by 79 · cited 1×
“Likewise, Jamal et al. [142] combined biological, chemical, and phenotypic properties to predict nervous system ADRs linked with drugs through machine learning analysis.”
BackgroundPADME: A Deep Learning-based Framework for Drug-Target Interaction Prediction
Feng, Q., Dueva, E., Cherkasov, A. R., & Ester, M. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1807.09741 · Cited by 79 · cited 1×
“DL approaches such as DeepDTA (https:// github. com/ hkmzt rk/ DeepD TA) [314], and PADME [315] predict drug-target binding affinity, which depends on the 3-”
MethodDeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials
Keshavarzi Arshadi, A., Salem, M., Collins, J., Yuan, J. S., & Chakrabarti, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01526 · Cited by 77
Ponzoni, I., Sebastián-Pérez, V., Martínez, M. J., Roca, C., De la Cruz Pérez, C., Cravero, F., Vazquez, G. E., Páez, J. A., Díaz, M. F., & Campillo, N. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-45522-3 · Cited by 75 · cited 2×
“Additionally, Ponzoni et al. 2019 made a QSAR model for finding inhibitors of the BACE1 enzyme, which is responsible for β-amyloid (Aβ) aggregation in AD.”
BackgroundMethodHe, S., Zhang, C., Zhou, P., Zhang, X., Ye, T., Wang, R., Sun, G., & Sun, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153633 · Cited by 75 · cited 1×
“For example, [67] applied a computational approach to screen the hepatotoxic ingredients in traditional Chinese medicines, whereas [68] demonstrated the phylogenetic relationship, structure–toxicity relationship, and herb-ingredient network using computational technique.”
MethodLiu, Y., Ren, Y., Cao, Y., Huang, H., Wu, Q., Li, W., Wu, S., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-12522-0 · Cited by 74 · cited 1×
“Likewise, Liu et al. 2017 discovered low toxicity O-GlcNAc transferase inhibitors, whereas Dou et al. [187] identified novel glycogen synthase kinase 3 beta (GSK-3β) inhibitors through SBVS [188].”
BackgroundRevisiting Warfarin Dosing Using Machine Learning Techniques
Sharabiani, A., Bress, A., Douzali, E., & Darabi, H. (2015) · Computational and Mathematical Methods in Medicine · doi:10.1155/2015/560108 · Cited by 72 · cited 1×
“They used relevance vector machines to classify different patients based on their dose demands, and then, regression models were used to predict appropriate doses for the patients [125].”
MethodDiscovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach
Leão, M., Pereira, C., Bisio, A., Ciribilli, Y., Paiva, A. M. O., Machado, N., Palmeira, A., Fernandes, M. X., Sousa, E., Pinto, M. M. M., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.032 · Cited by 71 · cited 1×
“…5 inhibitor in non-small cell lung cancer [190], identification of vascular endothelial growth factor receptor 2 potent compounds for the treatment of renal cell carcinoma [191], identification of multi-targeted inhibitors against breast cancer [192], and discovery of Mdm2-p53 inhibitor [193].”
BackgroundMachine intelligence decrypts β-lapachone as an allosteric 5-lipoxygenase inhibitor
Rodrigues, T., Werner, M., Roth, J., da Cruz, E. H. G., Marques, M. C., Akkapeddi, P., Lobo, S. A., Koeberle, A., Corzana, F., da Silva Júnior, E. N., et al. (2018) · Chemical Science · doi:10.1039/c8sc02634c · Cited by 71 · cited 1×
“Recently, other ML-based tools such as SPIDER [342] and read-across structure–activity relationships (RASAR) [343] were developed, which are capable of analyzing β-lapachone targets and linking molecular structures and toxic properties of an unknown compound, respectively.”
MethodGaussian Processes for Classification: QSAR Modeling of ADMET and Target Activity
Obrezanova, O., & Segall, M. D. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci900406x · Cited by 71
A multimodal deep learning-based drug repurposing approach for treatment of COVID-19
Hooshmand, S. A., Zarei Ghobadi, M., Hooshmand, S. E., Azimzadeh Jamalkandi, S., Alavi, S. M., & Masoudi-Nejad, A. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10144-9 · Cited by 70 · cited 1×
“For example, network-based drug repurposing identified 16 potential anti-HCoV repurposable drugs, whereas Hooshmand et al. 2020 identified 12 promising drug targets for COVID-19 based on the multimodal DL approach [285, 286].”
BackgroundJarada, T. N., Rokne, J. G., & Alhajj, R. (2021) · BMC Bioinformatics · doi:10.1186/s12859-020-03950-3 · Cited by 70
Zhou, W., Liu, X., Tu, Z., Zhang, L., Ku, X., Bai, F., Zhao, Z., Xu, Y. F., Ding, K., & Li, H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401045n · Cited by 69 · cited 1×
“…interaction in AD [370], prediction of the anticancer mechanism of Kushen Injection against Hepato-cellular carcinoma [371], and discovery of Pteridin-7(8H)- one-Based as therapeutic compound against epidermal growth factor receptor kinase T790M/L858R mutant [372], were performed using ChemMapper.”
MethodXu, Z., Yang, L., Zhang, X., Zhang, Q., Yang, Z., Liu, Y., Wei, S., & Liu, W. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.556481 · Cited by 69
Yousuf, Z., Iman, K., Iftikhar, N., & Mirza, M. U. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s132074 · Cited by 69 · cited 1×
“…5 inhibitor in non-small cell lung cancer [190], identification of vascular endothelial growth factor receptor 2 potent compounds for the treatment of renal cell carcinoma [191], identification of multi-targeted inhibitors against breast cancer [192], and discovery of Mdm2-p53 inhibitor [193].”
BackgroundDPubChem: a web tool for QSAR modeling and high-throughput virtual screening
Soufan, O., Ba-Alawi, W., Magana-Mora, A., Essack, M., & Bajić, V. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27495-x · Cited by 68
Raja, K., Patrick, M., Elder, J. T., & Tsoi, L. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-03914-3 · Cited by 67 · cited 1×
“Moreover, Raja et al. [144] used machine learning analysis to predict ADRs, which are a result of drug-drug interactions.”
BackgroundA deep neural network for molecular wave functions in quasi-atomic minimal basis representation
Gastegger, M., McSloy, A., Luya, M., Schütt, K. T., & Maurer, R. J. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0012911 · Cited by 67 · cited 1×
“Moreover, molecular dynamics (MD) simulation analyzes how molecules behave and interact at an atomistic level [79].”
BackgroundA novel drug repurposing approach for non-small cell lung cancer using deep learning
Li, B., Dai, C., Wang, L., Deng, H., Li, Y., Guan, Z., & Ni, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233112 · Cited by 67 · cited 2×
“Likewise, Li et al. 2020 constructed a computational framework of host-based drug repurposing for broad-spectrum antivirals against RNA virus.”
BackgroundDRIMC: an improved drug repositioning approach using Bayesian inductive matrix completion
Zhang, W., Xu, H., Li, X., Gao, Q., & Wang, L. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa062 · Cited by 66 · cited 1×
“…have been developed in recent times such as DrugNet (http:// genom e2. ugr. es/ drugn et/) [274], DRIMC (https:// github. com/ linwa ng1982/ DRIMC) [275], DPDR-CPI (http:// cpi. bio-x. cn/ dpdr/) [276], PHARMGKB (https:// www. pharm gkb. org/) [277], PRO-MISCUOUS 2.0 (http:// bioin forma tics.…”
InfluentialArtificial intelligence in the early stages of drug discovery
Cavasotto, C. N., & Di Filippo, J. I. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108730 · Cited by 65 · cited 1×
“This has not only encouraged the scientific community but has also resulted in the growing partnership between the pharmaceutical industry and AI companies [443].”
BackgroundChemSAR: an online pipelining platform for molecular SAR modeling
Dong, J., Yao, Z.-J., Zhu, M.-F., Wang, N.-N., Lu, B., Chen, A. F., Lu, A.-P., Miao, H., Zeng, W.-B., & Cao, D.-S. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0215-1 · Cited by 64
Interpretation of ANN‐based QSAR models for prediction of antioxidant activity of flavonoids
Žuvela, P., David, J., & Wong, M. W. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25168 · Cited by 64
The application of machine learning techniques to innovative antibacterial discovery and development
Serafim, M. S. M., Kronenberger, T., Oliveira, P. R., Poso, A., Honório, K. M., Mota, B. E. F., & Maltarollo, V. G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1776696 · Cited by 63
Ayati, A., Falahati, M., Irannejad, H., & Emami, S. (2012) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-20-46 · Cited by 63 · cited 1×
“…ug [ 420 ] vcclab. org/ lab/ pclie nt/) [304], E-DRAGON (http:// www. vcclab. org/ lab/ edrag on/) [304], ChemSpider (http:// www. chems pider. com/) [306], SPARC (http:// sparc. chem. uga. edu/ sparc/) [307], and OSIRIS property explorer (https:// www. organ ic-chemi stry. org/ prog/ peo/) [308].”
Abdel‐Basset, M., Hawash, H., Elhoseny, M., Chakrabortty, R. K., & Ryan, M. J. (2020) · IEEE Access · doi:10.1109/access.2020.3024238 · Cited by 62
Liu, X., Wu, J., Zhang, D., Wang, K., Duan, X., & Zhang, X. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/6517034 · Cited by 61
Kannan, S., Melesina, J., Hauser, A.-T., Chakrabarti, A., Heimburg, T., Schmidtkunz, K., Walter, A., Marek, M., Pierce, R. J., Romier, C., et al. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5004653 · Cited by 60 · cited 1×
“…Cruz et al. 2018 concluded that ZINC91881108 was potent compound against RIPK2, whereas Simoben et al. 2018 demonstrated eight novel N-(2,5-dioxopyrrolidin-3-yl)-n- alkylhydroxamate derivatives as smHDAC8 inhibitors with IC 50 values ranging from 4.4 to 20.3 µM against smHDAC8 [196, 197] [Fig.”
BackgroundInfluentialPred-binding: large-scale protein–ligand binding affinity prediction
Shar, P. A., Tao, W., Gao, S., Huang, C., Li, B., Zhang, W., Shahen, M., Zheng, C., Bai, Y., & Wang, Y. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1144594 · Cited by 60
Van Vleet, T. R., Liguori, M. J., Lynch, III, Rao, M., & Warder, S. (2019) · SLAS Discovery · doi:10.1177/2472555218799713 · Cited by 59
Fu, Y., Sun, Y.-N., Yi, K., Li, M., Cao, H., Li, J., & Ye, F. (2017) · Molecules · doi:10.3390/molecules22060959 · Cited by 59 · cited 1×
“…of aurora kinase A inhibitors [212], G-quadruplex-targeting chemo-types [213], PI3Kα inhibitors [214], targeting dengue virus non-structural protein 3 helicases [215], potential selective histone deacetylase 8 inhibitors [216], and novel p-Hydroxy-phenylpyruvate dioxygenase inhibitors [217].”
BackgroundJamal, S., Grover, A., & Grover, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00780 · Cited by 56 · cited 1×
“Further, [467] used descriptors derived from MD simulation trajectories of the caspase-8 protein–ligand complex to train ANN and RF models to find inhibitors of caspase 8 protease, a protease that has been implicated in AD pathogenesis.”
MethodBennett, W. F. D., He, S., Bilodeau, C. L., Jones, D., Sun, D., Kim, H., Allen, J. E., Lightstone, F. C., & Ingólfsson, H. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00318 · Cited by 56
Liu, H., Zhang, W., Song, Y., Deng, L., & Zhou, S. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01008 · Cited by 56
Puratchikody, A., Sriram, D., Umamaheswari, A., & Navabshan, I. (2016) · Chemistry Central Journal · doi:10.1186/s13065-016-0169-9 · Cited by 56 · cited 2×
“Further, Puratchikody et al. 2016 used ORISIS property explorer in their study to predict the quantitative structural toxicity of tyrosine derivates intended for safe, potent inflammation treatment.”
BackgroundTiming of the Brunhes-Matuyama transition constrained by U-series disequilibrium
Ghaleb, B., Falguères, C., Carlut, J., Pozzi, J. P., Mahieux, G., Boudad, L., & Rousseau, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-42567-2 · Cited by 56
Yin, Q., Fan, R., Cao, X., Liu, Q., Jiang, R., & Zeng, W. (2023) · Quantitative Biology · doi:10.15302/j-qb-022-0320 · Cited by 56
TarPred: a web application for predicting therapeutic and side effect targets of chemical compounds
Liu, X., Gao, Y., Peng, J., Xu, Y., Wang, Y., Zhou, N., Xing, J., Luo, X., Jiang, H., & Zheng, M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv099 · Cited by 55
Goel, A. K., & Davies, J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108770422.026 · Cited by 55 · cited 1×
“The term AI is commonly used when a machine mimics cognitive behavior associated with the human brain during learning and problem solving [7].”
BackgroundChembench: A Publicly Accessible, Integrated Cheminformatics Portal
Capuzzi, S. J., Kim, I. S.-J., Lam, W. I., Thornton, T. E., Muratov, E. N., Pozefsky, D., & Tropsha, A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00462 · Cited by 54
Wu, J., Zhang, Q., Wu, W., Pang, T., Hu, H., Chan, W. K. B., Ke, X., & Zhang, Y. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty070 · Cited by 54
Ligand-based approach for predicting drug targets and for virtual screening against COVID-19
Yang, Y., Zhu, Z., Wang, X., Zhang, X., Mu, K., Shi, Y., Peng, C., Xu, Z., & Zhu, W. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa422 · Cited by 54
PlayMolecule BindScope: large scale CNN-based virtual screening on the web
Skalic, M., Martínez-Rosell, G., Jiménez, J., & De Fabritiis, G. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty758 · Cited by 53 · cited 1×
“…enScr een/) [170], FlexX ‐ Scan [171], CompScore (http:// bioqu imio. udla. edu. ec/ comps core/) [172], PlayMolecule BindScope (PlayMol-ecule.org) [173], GeauxDock (http:// www. bryli nski. org/ geaux dock) [174], EasyVS (http:// biosig. unime lb. edu. au/ easyvs) [175], DEKOIS 2.0 [176],…”
InfluentialOh, M., Ahn, J., & Yoon, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111668 · Cited by 53 · cited 1×
“Furthermore, [474] proposed telmisartan as potential repurposed drug for AD by using a genetic network-driven classification model.”
MethodJiang, H.-J., Huang, Y.-A., & You, Z.-H. (2019) · BioMed Research International · doi:10.1155/2019/2426958 · Cited by 53 · cited 1×
“Jiang et al. 2019, using DeepAffinity, proposed a novel protein descriptor for identifying drug-target interaction, whereas Born et al. 2020 with the help of Deep Affinity, identified antiviral candidates for SARS-CoV-2 [319, 320].”
MethodJarada, T. N., Rokne, J. G., & Alhajj, R. (2020) · Knowledge-Based Systems · doi:10.1016/j.knosys.2020.106585 · Cited by 53 · cited 1×
“For example, SNF-CVAE based on drug similarity network fusion identified promising therapeutic agents for Alzheimer’s disease (AD) and juvenile rheumatoid arthritis, whereas DTI-RCNN based on neural network algorithm and integrates long short-term memory predicts drug-target interactions [287, 288].”
BackgroundJiang, H.-J., Huang, Y., & You, Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-61616-9 · Cited by 53
Chen, H., Chen, J., Li, J., Huang, H.-J., Chen, X., Zhang, H.-Y., & Chen, C. Y. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00041 · Cited by 53 · cited 2×
“In another study, [468] used data from a traditional Chinese medicine database, followed by VS, molecular docking, and ML techniques, including DL, to find inhibitors of GSK3β, an enzyme implicated in AD.”
MethoddendPoint: a web resource for dendrimer pharmacokinetics investigation and prediction
Kaminskas, L. M., Pires, D. E. V., & Ascher, D. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-51789-3 · Cited by 53
Gu, S., & Lai, L. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0306-9 · Cited by 53
Cañada, A., Capella-Gutiérrez, S., Rabal, O., Oyarzábal, J., Valencia, A., & Krallinger, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx462 · Cited by 53 · cited 1×
“For this different web-based tools have been developed such as LimTox (http:// limtox. bioin fo. cnio. es/) [321], pkCSM (http:// biosig. unime lb. edu. au/ pkcsm/) [322], admetSAR (http:// lmmd. ecust. edu. cn/ admet sar2/) [323], and Toxtree (http:// toxtr ee. sourc eforge. net/) [324].”
MethodDebnath, S., Debnath, T., Bhaumik, S., Majumdar, S., Kalle, A. M., & Vema, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-53376-y · Cited by 52 · cited 1×
“…of aurora kinase A inhibitors [212], G-quadruplex-targeting chemo-types [213], PI3Kα inhibitors [214], targeting dengue virus non-structural protein 3 helicases [215], potential selective histone deacetylase 8 inhibitors [216], and novel p-Hydroxy-phenylpyruvate dioxygenase inhibitors [217].”
BackgroundLi, H., Leung, K.-S., Wong, M.-H., & Ballester, P. J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw320 · Cited by 52 · cited 1×
“…(http:// www. swiss simil arity. ch/) [198], METADOCK [199], Open-source platform [200], HybridSim-VS (http:// www. rcidm. org/ Hybri dSim-VS/) [201], PKRank [202], PyGOLD (http:// www. agkoch. de/) [203], BRUSELAS (http:// bio-hpc. eu/ softw are/ Bruse las) [204], RADER (http:// rcidm. org/…”
Chen, P., Ke, Y., Lu, Y., Du, Y., Li, J., Hui, Y., Zhao, H., Zhou, Y., & Yang, Y. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0373-4 · Cited by 52 · cited 1×
“Further, chen et al. 2019 used the STITCH database to find targets of potential drugs short-listed for esophageal carcinoma [351].”
MethodRobledo‐Cadena, D. X., Gallardo‐Pérez, J. C., Dávila‐Borja, V. M., Pacheco-Velázquez, S. C., Belmont-Díaz, J., Ralph, S. J., Blanco-Carpintero, B. A., Moreno‐Sánchez, R., & Rodríguez‐Enríquez, S. (2020) · Pharmaceuticals · doi:10.3390/ph13120463 · Cited by 51 · cited 2×
“…anti-inflammatory drugs on cisplatin, paclitaxel, and doxorubicin efficacy against cervix cancer cells using PrOCTOR, whereas Gilvary et al. 2020 identified the novel indications for 2,576 small molecules incorporated with 16 different drug features for PD and Type 2 diabetes [336, 337].”
MethodArtificial Intelligence in Drug Design—The Storm Before the Calm?
Jordan, A. M. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00500 · Cited by 50 · cited 1×
“Moreover, the increase in data digitization in the pharmaceutical companies and healthcare sector motivates the implementation of AI to overcome the problems of scru-tinizing the complex data [6].”
BackgroundZHU, Q., TAO, C., SHEN, F., & CHUTE, C. G. (2013) · Biocomputing 2014 · doi:10.1142/9789814583220_0017 · Cited by 50 · cited 1×
“…DRIMC (https:// github. com/ linwa ng1982/ DRIMC) [275], DPDR-CPI (http:// cpi. bio-x. cn/ dpdr/) [276], PHARMGKB (https:// www. pharm gkb. org/) [277], PRO-MISCUOUS 2.0 (http:// bioin forma tics. chari te. de/ promi scuou s2) [278], and DRRS (http:// bioin forma tics. csu. edu. cn/ resou rces/…”
InfluentialLarge-Scale Ligand-Based Virtual Screening for SARS-CoV-2 Inhibitors Using Deep Neural Networks
Hofmarcher, M., Mayr, A., Rumetshofer, E., Ruch, P., Renz, P., Schimunek, J., Seidl, P., Vall, A., Widrich, M., Hochreiter, S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3561442 · Cited by 49
Taha, K. F., Khalil, M. S. M., Bakr, M. S. A., et al. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112413 · Cited by 49 · cited 1×
“Likewise, Taha et al. 2020 used the STITCH database to find targets for active constituents of Nandina domestica, a plant used for treating various tumors.”
MethodNabirotchkin, S., Peluffo, A. E., Bouaziz, J., & Cohen, D. (2020) · Preprints.org · doi:10.20944/preprints202003.0302.v1 · Cited by 49
Lynch, Bothwell, & al., L. C. E. (2007) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831.77.2.107 · Cited by 48 · cited 1×
“Thus, the physicochemical properties of compounds must be considered while designing a novel drug molecule [100, 298].”
BackgroundArtificial intelligence-based classification of breast cancer using cellular images
Tripathy, R. K., Mahanta, S. K., & Paul, S. (2014) · RSC Advances · doi:10.1039/c3ra47489e · Cited by 48 · cited 1×
“To classify the target cell, firstly, the ML model needs to be trained so that it can identify the cell and its features, which is basically done by contrasting the image of the targeted cells, which separates it from the background [96].”
BackgroundIn Silico Prediction of PAMPA Effective Permeability Using a Two-QSAR Approach
Chi, C.-T., Lee, M.-H., Weng, C.-F., & Leong, M. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133170 · Cited by 48 · cited 2×
“The authors concluded that the HSVR scheme executed better than the PLS scheme in the training set, test set, and statistical analysis [66].”
MethodHe, S., Zhang, X., Lu, S., Zhu, T., Sun, G., & Sun, X. (2019) · Biomolecules · doi:10.3390/biom9100577 · Cited by 48 · cited 1×
“For example, [67] applied a computational approach to screen the hepatotoxic ingredients in traditional Chinese medicines, whereas [68] demonstrated the phylogenetic relationship, structure–toxicity relationship, and herb-ingredient network using computational technique.”
MethodWhen less is more – efficacy with less toxicity at the ED50
Dimmitt, S. B., Stampfer, H. G., & Martin, J. H. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13281 · Cited by 46 · cited 1×
“Over the years, it has been challenging to ascertain the optimum dose of a drug that can achieve the desired efficacy with minimum toxic side effects [121].”
BackgroundMusumeci, D., Amato, J., Zizza, P., Platella, C., Cosconati, S., Cingolani, C., Biroccio, A., Novellino, E., Randazzo, A., Giancola, C., et al. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.01.024 · Cited by 45 · cited 1×
“…potential implementation of AI algorithms in LBVS such as identification of aurora kinase A inhibitors [212], G-quadruplex-targeting chemo-types [213], PI3Kα inhibitors [214], targeting dengue virus non-structural protein 3 helicases [215], potential selective histone deacetylase 8 inhibitors…”
Method[20] Data Storage and Analysis in ArrayExpress
Brāzma, A., Kapushesky, M., Parkinson, H., Sarkans, U., & Shojatalab, M. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)11020-4 · Cited by 45 · cited 1×
“…of appropriate targets (e.g., genes, proteins) involved in disease pathophysiology, followed by finding suitable drugs or drug-like molecules which can meddle with these targets, and now we have access to a constellation of biomedical data repositories which can help us in this regard [39].”
BackgroundShao, Y.-M., Ma, X., Paira, P., Tan, A., Herr, D. R., Lim, K. L., Ng, C. H., Venkatesan, G., Klotz, K.-N., Federico, S., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0188212 · Cited by 45 · cited 3×
“…of Naïve Bayes networks to find potent and safe abelson tyrosine-protein kinase 1 (c-Abl) inhibitors, which promote neuroprotection in PD. Likewise, Shao et al. 2018 used integration of SVM algorithm and Tanimoto similarity-based clustering, followed by in vitro experiments, to find novel…”
MethodA New Algorithm Optimized for Initial Dose Settings of Vancomycin Using Machine Learning
Imai, S., Takekuma, Y., Miyai, T., & Sugawara, M. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00729 · Cited by 45
IVS2vec: A tool of Inverse Virtual Screening based on word2vec and deep learning techniques
Zhang, H., Liao, L., Cai, Y., Hu, Y., & Wang, H. (2019) · Methods · doi:10.1016/j.ymeth.2019.03.012 · Cited by 44 · cited 1×
“…eu/ softw are/ Bruse las) [204], RADER (http:// rcidm. org/ rader/) [205], QEX [206], IVS2vec (https:// github. com/ haipi ng1010/ IVS2V ec) [207], AutoDock Bias (http:// autod ockbi as. wordp ress. com/) [208], Ligity [209], D3Similarity (https:// www. d3pha rma. com/ D3Tar gets-…”
TrixX: structure-based molecule indexing for large-scale virtual screening in sublinear time
Schellhammer, I., & Rarey, M. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9103-5 · Cited by 44
Andrýsek, T. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00077-4 · Cited by 44
Sharma, K., Patidar, K., Ali, M. A., et al. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181130142237 · Cited by 44 · cited 1×
“…5 inhibitor in non-small cell lung cancer [190], identification of vascular endothelial growth factor receptor 2 potent compounds for the treatment of renal cell carcinoma [191], identification of multi-targeted inhibitors against breast cancer [192], and discovery of Mdm2-p53 inhibitor [193].”
BackgroundImprovement of Adequate Digoxin Dosage: An Application of Machine Learning Approach
Hu, Y.-H., Tai, C.-T., Tsai, C.-F., & Huang, M.-W. (2018) · Journal of Healthcare Engineering · doi:10.1155/2018/3948245 · Cited by 43 · cited 1×
“Moreover, Hu et al. [128] performed ML analysis with techniques like classification and regression trees, multilayer perceptron network, k-nearest neighbor to find out the safe initial dose of cardiac drug digoxin.”
MethodWei, Y., Li, W., Du, T., Hong, Z., & Lin, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143572 · Cited by 43
Cruz, J. V., Neto, M. F. D. A., Silva, L. B., Ramos, R. D. S., Costa, J. D. S., Brasil, D. D. S. B., Lobato, C. C., da Costa, G. V., Bittencourt, J. A. H. M., da Silva, C. H. T. D. P., et al. (2018) · Molecules · doi:10.3390/molecules23020453 · Cited by 43 · cited 2×
“…Cruz et al. 2018 concluded that ZINC91881108 was potent compound against RIPK2, whereas Simoben et al. 2018 demonstrated eight novel N-(2,5-dioxopyrrolidin-3-yl)-n- alkylhydroxamate derivatives as smHDAC8 inhibitors with IC 50 values ranging from 4.4 to 20.3 µM against smHDAC8 [196, 197] [Fig.”
BackgroundInfluentialYang, C., Wang, W., Chen, L., Liang, J., Lin, S., Lee, M.-Y., Ma, D., & Leung, C. (2016) · Chemical Communications · doi:10.1039/c6cc04938a · Cited by 42 · cited 1×
“…signal transducer and activator of transcription 3 dimerization inhibitor [184], prediction of VHL and hypoxia-inducible factor 1-alpha inhibitors [185], and prediction of Kelch-like ECH-associated protein-nuclear factor erythroid 2-related factor 2 (Keap-Nrf2) small-molecule inhibitors [186].”
BackgroundWang, Q., Feng, Y., Huang, J., Wang, T., & Cheng, G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0176486 · Cited by 42 · cited 1×
“Moreover, AI in drug development opened the gates for identifying molecular pathways or molecular targets for the treatment of human disease through genomics information, biochemical features, and target specifications [373].”
BackgroundACP-GCN: The Identification of Anticancer Peptides Based on Graph Convolution Networks
Rao, B., Zhang, L., & Zhang, G. (2020) · IEEE Access · doi:10.1109/access.2020.3023800 · Cited by 42 · cited 1×
“In addition, Rao et al. 2020 combined a graphical convolutional network and one-hot encoding to design ACP-GCN for the discovery of anti-cancer peptides [116].”
BackgroundSrivastava, A., Siddiqui, S., Ahmad, R., Mehrotra, S., Ahmad, B., & Srivastava, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1835725 · Cited by 42 · cited 2×
“Srivastava et al. 2020 used admetSAR to evaluate the toxicity of Withania somnif-era as a therapeutic compound against COVID-19, whereas Uygun et al. 2021 incorporated pkCSM for the identification of the therapeutic effect and toxicological properties of pyrazolo[1,5-a]pyrazine-4(5H)-one derivative…”
BackgroundMethodMeng, C., Hu, Y., Zhang, Y., & Guo, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00245 · Cited by 42
Wu, X., Wei, Z., Chen, K., Zhang, Q., Su, J., Liu, H., Zhang, L., & Meng, J. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2840-3 · Cited by 42
RepCOOL: computational drug repositioning via integrating heterogeneous biological networks
Fahimian, G., Zahiri, J., Arab, S. S., & Sajedi, R. H. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02541-3 · Cited by 42 · cited 1×
“The results concluded that doxorubicin, paclitaxel, trastuzumab, and tamoxifen were potential therapeutic agents against breast cancer stage II [282].”
BackgroundHermansyah, O., Bustamam, A., & Yanuar, A. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107597 · Cited by 42
Ibrahim, T. M., Bauer, M. R., & Boeckler, F. M. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0074-6 · Cited by 41 · cited 1×
“…[173], GeauxDock (http:// www. bryli nski. org/ geaux dock) [174], EasyVS (http:// biosig. unime lb. edu. au/ easyvs) [175], DEKOIS 2.0 [176], PL-PatchSurfer2 (http:// www. kihar alab. org/ plps2/) [177], SPOT-ligand 2 (http:// sparks-lab. org/) [178], Gypsum-DL (https:// durra ntlab.…”
InfluentialLee, H., & Kim, W. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080377 · Cited by 41 · cited 1×
“Similarly, Lee and Kim 2019 predicted the drug-target interactions by DNN based on large-scale drug-induced transcriptome data using PADME [317].”
BackgroundTian, Y., Zhang, S., Yin, H., & Yan, A. (2019) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2019.103888 · Cited by 39
Turning genome-wide association study findings into opportunities for drug repositioning
Lau, A., & So, H. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.06.015 · Cited by 39 · cited 1×
“Further, genome-wide association studies (GWAS) can determine the interrelation of genomic variants with particular complex disorders [45].”
BackgroundMontanari, F., Knasmuller, B., Kohlbacher, S. M., Hillisch, C., Baierová, C., Grandits, M., & Ecker, G. F. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00899 · Cited by 39
StackCBPred: A stacking based prediction of protein-carbohydrate binding sites from sequence
Gattani, S., Mishra, A., & Hoque, M. T. (2019) · Carbohydrate Research · doi:10.1016/j.carres.2019.107857 · Cited by 38
Cheminformatics at the interface of medicinal chemistry and proteomics
Koch, U., Hamacher, M., & Nußbaumer, P. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.05.010 · Cited by 38
Discovery of Novel HIV Entry Inhibitors for the CXCR4 Receptor by Prospective Virtual Screening
Pérez‐Nueno, V. I., Pettersson, S., Ritchie, D. W., Borrell, J. I., & Teixidó, J. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800468q · Cited by 38 · cited 1×
“Apart from these mentioned studies number of literature validated the possible implementation of AI in LBVS, such as identification of HIV entry inhibitors and potent inhibitors of DNA methyltransferase [218, 219].”
BackgroundPROMISCUOUS 2.0: a resource for drug-repositioning
Gallo, K., Goede, A., Eckert, A. P., Moahamed, B., Preißner, R., & Gohlke, B.-O. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1061 · Cited by 38 · cited 1×
“…DPDR-CPI (http:// cpi. bio-x. cn/ dpdr/) [276], PHARMGKB (https:// www. pharm gkb. org/) [277], PRO-MISCUOUS 2.0 (http:// bioin forma tics. chari te. de/ promi scuou s2) [278], and DRRS (http:// bioin forma tics. csu. edu. cn/ resou rces/ softs/ DrugR eposi tioni ng/ DRRS/ index. html) [279].”
InfluentialEnsemble learning method for the prediction of new bioactive molecules
Afolabi, L. T., Saeed, F., Hashim, H., & Petinrin, O. O. (2018) · PLoS ONE · doi:10.1371/journal.pone.0189538 · Cited by 38 · cited 1×
“Moreover, Afolabi et al. [138] used data from the MLD drug data report (MDDR) repository and applied it to a combination of boosting algorithms to identify novel bioactive compounds.”
MethodWang, Q., Xu, J., Li, Y., Huang, J., Jiang, Z., Wang, Y., Liu, L., Leung, E. L., & Yao, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00173 · Cited by 38 · cited 1×
“…for treatment of acute myeloid leukemia [189], identification of novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer [190], identification of vascular endothelial growth factor receptor 2 potent compounds for the treatment of renal cell carcinoma [191],…”
BackgroundRADER: a RApid DEcoy Retriever to facilitate decoy based assessment of virtual screening
Wang, L., Pang, X., Li, Y., Zhang, Z., & Tan, W. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw783 · Cited by 37 · cited 1×
“…[202], PyGOLD (http:// www. agkoch. de/) [203], BRUSELAS (http:// bio-hpc. eu/ softw are/ Bruse las) [204], RADER (http:// rcidm. org/ rader/) [205], QEX [206], IVS2vec (https:// github. com/ haipi ng1010/ IVS2V ec) [207], AutoDock Bias (http:// autod ockbi as. wordp ress. com/) [208], Ligity…”
Browne, F., Zheng, H., Wang, H., & Azuaje, F. J. (2010) · Advances in Artificial Intelligence · doi:10.1155/2010/924529 · Cited by 37 · cited 1×
“PPIs prediction can be identified as direct PPI, direct PPI with indirect functional associations and PPIs for signal transduction pathways [147].”
BackgroundYu, M., Gu, Q., & Xu, J. (2018) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-017-0092-8 · Cited by 36 · cited 1×
“…of AI algorithms in LBVS such as identification of aurora kinase A inhibitors [212], G-quadruplex-targeting chemo-types [213], PI3Kα inhibitors [214], targeting dengue virus non-structural protein 3 helicases [215], potential selective histone deacetylase 8 inhibitors [216], and novel…”
MethodHalim, S. A., Khan, S. R., Khan, A., et al. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00088 · Cited by 36 · cited 1×
“…of aurora kinase A inhibitors [212], G-quadruplex-targeting chemo-types [213], PI3Kα inhibitors [214], targeting dengue virus non-structural protein 3 helicases [215], potential selective histone deacetylase 8 inhibitors [216], and novel p-Hydroxy-phenylpyruvate dioxygenase inhibitors [217].”
BackgroundLuo, H., Zhang, P., Cao, X. H., Du, D., Ye, H., Huang, H., Li, C., Qin, S., Wan, C., Shi, L. M., et al. (2016) · Scientific Reports · doi:10.1038/srep35996 · Cited by 35
Research works printed but not linked: 5
- Carpenter KA, Huang X (2018) Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: a review. Curr Pharm Des. https://doi.org/10.2174/1381612824666180607124038 · DOI · Paper page
- Gad SC (2014) QSAR. In: Third E (ed) Wexler PBT- Encyclopedia of Toxicology. Academic Press, Oxford, pp 1–9
- Royal Society of Chemistry (2015) ChemSpider. Search and Share Chemistry. R. Soc, Chem
- Cao X, Fan R, Zeng W (2020) DeepDrug: a general graph-based deep learning framework for drug relation prediction. biorxiv. https://doi.org/10.1101/2020.11.09.375626 · DOI
- Harrer S, Shah P, Antony B, Hu J (2019) Artificial intelligence for clinical trial design. Trends Pharmacol Sci 40:577–591. https://doi.org/10.1016/j.tips.2019.05.005 · DOI · Paper page
Cited by
The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century
Maleki Varnosfaderani, S., & Forouzanfar, M. (2024) · Bioengineering · doi:10.3390/bioengineering11040337 · Cited by 931
“By analyzing historical data from clinical trials and patient records, AI models can predict the effectiveness of drugs on various demographic groups [44,45].”
MethodThe role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
“Today, AI-based technologies have been applied to virtually every step in the drug discovery process, including target identification, drug design, drug screening, chemical synthesis, and prediction of the drug’s properties and mode of action.(341,342) In addition, AI can be used to quickly identify lead compounds ext…”
Metaverse for Healthcare: A Survey on Potential Applications, Challenges and Future Directions
Chengoden, R., Victor, N., Huynh-The, T., Yenduri, G., Jhaveri, R. H., Alazab, M., Bhattacharya, S., Hegde, P., Maddikunta, P. K. R., & Gadekallu, T. R. (2023) · IEEE Access · doi:10.1109/access.2023.3241628 · Cited by 508
“Artificial intelligence (AI), also known as machine intelligence, focuses on the development and management of technology that can autonomously learn to make decisions and carry out tasks on behalf of humans [90].”
BackgroundClinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
“Machine-learning and AI technology have the potential to accelerate the process of drug development, reducing failure rates, and increasing the accuracy of predictions [20, 177].”
Background
Metadata
- Authors
- Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P.
- Affiliations
- Delhi Technological University (IN)
- Corresponding author
- Kumar, Pravir
- Venue
- Molecular Diversity
- Published
- 2021-04-12
- Volume
- 25
- Issue
- 3
- Pages
- 1315-1360
- ISSN
- 1381-1991 (ISSN-L)
- 1573-501X
- PMC
- PMC8040371
- OpenAlex
- W3153418506
- Semantic Scholar
- 29409efa04ac99ccf01d2a011d21d5d14e870000
- Cited by
- 1,473
- References
- 503
- Citations by year
- 2026: 221 · 2025: 438 · 2024: 397 · 2023: 272 · 2022: 113 · 2021: 31
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Molecular Diversity (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- artificial intelligence in drug discovery, deep learning, computer-aided drug design, virtual screening, structure-based virtual screening, ligand-based virtual screening, QSAR, pharmacophore modeling, drug repurposing, polypharmacology, toxicity prediction, generative adversarial networks, molecular docking, protein misfolding, biomarker development, drug release monitoring
- MeSH terms
- Machine Learning, Drug Development, Deep Learning, Big Data, Algorithms, Animals, Artificial Intelligence, Humans, Models, Molecular, Research Design, Drug Design, Quantitative Structure-Activity Relationship, Drug Discovery, Data Mining, Chemistry Techniques, Synthetic, Support Vector Machine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.